Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biosergen ABFRA:8N10 18 Market Cap is €1.28 Mil as of Aug. 01, 2026. GuruFocus rates FRA:8N10 with a GF Score™ of 18/100. Among 1,422 Biotechnology companies, Biosergen AB ranks worse than 96.62% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Biosergen AB's share price for the quarter that ended in Dec. 2025 was €3.384. Biosergen AB's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 2.35 Mil. Therefore, Biosergen AB's market cap for the quarter that ended in Dec. 2025 was €7.95 Mil.
Biosergen AB's quarterly market cap
increased
from Jun. 2025 (€8.83 Mil) to Sep. 2025 (€10.00 Mil) but then
declined
from Sep. 2025 (€10.00 Mil) to Dec. 2025 (€7.95 Mil).
Biosergen AB's annual market cap
increased
from Dec. 2023 (€3.80 Mil) to Dec. 2024 (€10.75 Mil) but then
declined
from Dec. 2024 (€10.75 Mil) to Dec. 2025 (€7.95 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biosergen AB's Enterprise Value for Today is €-0.12 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Biosergen AB Market Cap Related Terms
Biosergen AB Market Cap Historical Data
* Premium members only.
The historical data trend for Biosergen AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8N10 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Biosergen AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosergen AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biosergen AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Biosergen AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Biosergen AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosergen AB (FRA:8N10) has a Market Cap of €1.28 Mil as of Aug. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biosergen AB and its competitors. According to the industry distribution chart, Biosergen AB ranks #1374 out of 1422 companies in the Biotechnology industry, placing it in the top 96.6%.
Is Biosergen AB's Market Cap too high?
Biosergen AB's current Market Cap is €1.28 Mil. Based on the distribution chart, Biosergen AB ranks #1374 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biosergen AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biosergen AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biosergen AB ranks #1374 out of 1422 companies for Market Cap. This places Biosergen AB in the lower half of its industry. The industry median Market Cap is 109.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 109.62, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biosergen AB and its competitors. For the Biotechnology industry, the median Market Cap is 109.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosergen AB's current Market Cap is €1.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosergen AB stock overvalued right now?
Biosergen AB (FRA:8N10) has a current Market Cap of €1.28 Mil. The current Market Cap is €1.28 Mil. Biosergen AB's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Biosergen AB (FRA:8N10), the current Market Cap is €1.28 Mil as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen' s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.
18GF Score
Get the complete analysis for FRA:8N10
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8N10 has been successfully added to your 
